摘要
子宮漿液性內膜癌乃一甚為惡性的第II型子宮內膜癌，有較多的局部和遠處轉移，建議治療方式有分期手術、放射線治療和化學治療等。最近，分子醫學的檢查和新藥物的使用，被證實對這類患者的治療效果佳，可增加存活時間比率。在有HER2顯示的患者，加入trastuzumab藥物對治療會有益處，因此建議晚期患者儘早檢查HER2；更且，晚期和復發性患者如使用pembrolizumab和lenvatinib治療，有效反應也可達50%。
並列摘要
Uterine serous carcinoma (USC) is a biologically aggressive type II endometrial cancer, and USC patients are at risk for both regional and distant metastasis, therapeutic guidelines recommend multimodality treatment including complete staging operation, radiotherapy, and chemotherapy. Recent advances in molecular evaluation and treatment of this disease have demonstrated significant benefits in survival outcomes. For HER2 expression in uterine serous carcinoma, the addition of trastuzumab to the therapeutic regimen for patients should be considered, therefore suggesting early testing for HER2 for advanced disease. Furthermore, the administration of pembrolizumab and lenvatinib is considered an essential treatment modality for second-line treatment of advanced stage and recurrence of USC patients, with an objective response rate of 50%.
延伸閱讀
- 陳冠宇、莊其穆、李以樂、楊思婷、江岭諭、王鵬惠（2019）。低分化漿液型子宮頸腺癌病例報告。婦癌醫學期刊，(50)，14-19。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-201910-201910050006-201910050006-14-19
- 宋永魁（2015）。早期子宮內膜癌的治療探索。婦癌醫學期刊，(42)，1-6。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-201510-201601140011-201601140011-1-6
- 吳孟浩、張國華、賴允亮、王銘志（1997）。晚期子宮內膜癌。放射治療與腫瘤學，4(1)，49-56。https://doi.org/10.6316/TRO/199704(1)49
- 李耀泰、陳福民、郭宗正（2020）。早期子宮內膜乳突狀漿液性腺癌的檢視。婦癌醫學期刊，(52)，25-28。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202010-202012160009-202012160009-25-28
- 李耀泰、陳福民、趙德讓、郭宗正（2007）。Uterine Papillary Serous Carcinoma。中華民國婦癌醫學雜誌，(2007年1)，45-50。https://doi.org/10.7010/JGO.200704.0045